Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

Description: Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease.

Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer.

However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period. Additionally, current market conditions are favorable for new mAbs, with high pricing patterns and weak impact from biosimilar exposure. As a result of this, GBI Research believes the global market has the potential to grow to a value of $766m by 2019.

Scope

- A brief introduction to the two indications, including the disease's pathogenesis, risk factors, diagnosis and treatment algorithms.

- In-depth analysis of Herceptin, including analysis of its safety, efficacy, treatment patterns and strengths/weaknesses.

- A comprehensive review of the pipeline for mAbs in gastric and esophageal cancer, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.

- Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.

- Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Canada, Japan, Germany, the UK, France, Italy and Spain.

- Discussion of the drivers and barriers for market growth.

Reasons to buy

- Understand the unmet need in the treatment of these cancers, the role of Herceptin and the areas of opportunity for other mAbs to enter the market.

- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.

- Observe the trends in clinical trial duration, size and molecule types across the phases of development and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for mAbs in gastric and esophageal cancers.

- Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs.

- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the market for mAbs in gastric and esophageal cancers.
6.1 Licensing Agreements
6.1.1 Gastric Cancer
6.1.2 Esophageal Cancer
6.2 Co-Development Agreements
6.2.1 Gastric Cancer
6.2.2 Esophageal Cancer

7 Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 References
7.4 All Pipeline Products, by Stage of Development
7.4.1 Gastric Cancer
7.4.2 Esophageal Cancer
7.5 Tabular Forecast Data
7.5.1 Gastric Cancer
7.5.2 Esophageal Cancer
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Therapeutic Landscape
7.6.4 Epidemiology-Based forecasting
7.6.5 Market Size by Geography
7.6.6 Geographical Landscape
7.6.7 Pipeline Analysis
7.6.8 Competitive Landscape
7.6.9 Expert Panel Validation
7.7 Contact Us
7.8 Disclaimer

1.1 List of Tables
Table 1: Market for mAbs in Gastrointestinal Tract Cancer, US, Epidemiology, 2008
Table 2: Market for mAbs in Gastrointestinal Tract Cancer, US, Diagnosis by Stage, 2008
Table 3: Market for mAbs in Gastrointestinal Tract Cancer, US, Five-Year Relative Survival by Stage, 2003-2009
Table 4: Market for mAbs in Gastric Cancer, Global, TNM Staging, 2010-2013
Table 5: Gastric Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013
Table 6: Gastric Cancer Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013
Table 7: Gastric Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013
Table 8: Gastric Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013
Table 9: Gastric Cancer Therapeutics, Global, All Pipeline Products (Phase III and Pre-registration), 2013
Table 10: Gastric Cancer Therapeutics, Global, All Pipeline Products (Undisclosed), 2013
Table 11: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013
Table 12: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013
Table 13: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013
Table 14: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013
Table 15: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Phase III and Pre-registration), 2013
Table 16: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Undisclosed), 2013
Table 17: Market for mAbs in Gastric Cancer, Global, Forecast Data, 2012-2019
Table 18: Market for mAbs in Gastric Cancer, US, Forecast Data, 2012-2019
Table 19: Market for mAbs in Gastric Cancer, Canada, Forecast Data, 2012-2019
Table 20: Market for mAbs in Gastric Cancer, UK, Forecast Data, 2012-2019
Table 21: Market for mAbs in Gastric Cancer, France, Forecast Data, 2012-2019
Table 22: Market for mAbs in Gastric Cancer, Germany, Forecast Data, 2012-2019
Table 23: Market for mAbs in Gastric Cancer, Italy, Forecast Data, 2012-2019
Table 24: Market for mAbs in Gastric Cancer, Spain, Forecast Data, 2012-2019
Table 25: Market for mAbs in Gastric Cancer, Japan, Forecast Data, 2012-2019
Table 26: Market for mAbs in Esophageal Cancer, Global, Forecast Data, 2012-2019
Table 27: Market for mAbs in Esophageal Cancer, US, Forecast Data, 2012-2019
Table 28: Market for mAbs in Esophageal Cancer, Canada, Forecast Data, 2012-2019
Table 29: Market for mAbs in Esophageal Cancer, UK, Forecast Data, 2012-2019
Table 30: Market for mAbs in Esophageal Cancer, France, Forecast Data, 2012-2019
1.2 List of Figures

Figure 1: Gastric Cancer: Treatment Algorithm
Figure 2: Esophageal Cancer: Treatment Algorithm (Locoregional Tumor)
Figure 3: Market for mAbs in Gastrointestinal Tract Cancer, Global, Sales of Herceptin ($bn), 1999-2012
Figure 4: Market for mAbs in Gastric Cancer, Global, Overall Pipeline, 2013
Figure 5: Market for mAbs in Gastric Cancer, Global, Pipeline mAbs by Mechanism of Action and Molecular Target, 2013
Figure 6: Market for mAbs in Gastric Cancer, Global, Developmental Pipeline Failure Rate, 2006-2013
Figure 7: Market for mAbs in Gastric Cancer, Global, Clinical Trial Sizes, 2006-2013
Figure 8: Market for mAbs in Gastric Cancer, Global, Clinical Trial Sizes by Molecule Type, 2006-2013
Figure 9: Market for mAbs in Gastric Cancer, Global, Clinical Trial Durations, 2006-2013
Figure 10: Market for mAbs in Gastric Cancer, Global, Clinical Trial Durations by Molecule Type, 2006-2013
Figure 11: Market for mAbs in Gastric Cancer, Global, Clinical Trial Primary Endpoints (All Molecule Types), 2006-2013
Figure 12: Market for mAbs in Gastric Cancer, Global, Clinical Trial Primary Endpoints (mAbs Only), 2006-2013
Figure 13: Market for mAbs in Gastric Cancer, Global, Clinical Trial Primary Endpoints by Developmental Program (mAbs Only), 2006-2013
Figure 14: Market for mAbs in Esophageal Cancer, Global, Overall Pipeline, 2013
Figure 15: Market for mAbs in Esophageal Cancer, Global, Pipeline mAbs by Mechanism of Action, 2013
Figure 16: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Sizes, 2006-2013
Figure 17: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Sizes by Molecule Type, 2006-2013
Figure 18: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Durations, 2006-2013
Figure 19: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Durations by Molecule Type, 2006-2013
Figure 20: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Primary Endpoints (All Molecule Types), 2006-2012
Figure 21: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Primary Endpoints (mAbs Only), 2006-2012
Figure 22: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Primary Endpoints by Developmental Program (mAbs Only), 2006-2012
Figure 23: Market for mAbs in Gastric Cancer, Global, Market Size and Growth, 2012-2019
Figure 24: Market for mAbs in Gastric Cancer, Global, Market Size and Growth, 2012-2019
Figure 25: Market for mAbs in Gastric Cancer, Global, Treatment Usage Patterns, 2012-2019
Figure 26: Market for mAbs in Gastric Cancer, Global, Market Size ($m), 2012-2019
Figure 27: Market for mAbs in Gastric Cancer, US, Treatment Patterns, 2012-2019
Figure 28: Market for mAbs in Gastric Cancer, US, Market Size ($m), 2012-2019
Figure 29: Market for mAbs in Gastric Cancer, Canada, Treatment Usage Patterns, 2012-2019
Figure 30: Market for mAbs in Gastric Cancer, Canada, Market Size ($m), 2012-2019
Figure 31: Market for mAbs in Gastric Cancer, Top Five European Markets, Treatment Usage Patterns, 2012-2019
Figure 32: Market for mAbs in Gastric Cancer, Top Five European Markets, Annual Cost of Therapy, 2012-2019
Figure 33: Market for mAbs in Gastric Cancer, Top Five European Markets, Market Size ($m), 2012-2019
Figure 34: Market for mAbs in Gastric Cancer, Japan, Treatment Usage Patterns, 2012-2019
Figure 35: Market for mAbs in Gastric Cancer, Japan, Market Size ($m), 2012-2019
Figure 36: Market for mAbs in Esophageal Cancer, Global, Treatment Usage Patterns, 2012-2019
Figure 37: Market for mAbs in Esophageal Cancer, Global, Market Size ($m), 2012-2019
Figure 38: Market for mAbs in Esophageal Cancer, US, Treatment Patterns, 2012-2019
Figure 39: Market for mAbs in Esophageal Cancer, US, Market Size ($m), 2012-2019
Figure 40: Market for mAbs in Esophageal Cancer, Canada, Treatment Patterns, 2012-2019
Figure 41: Market for mAbs in Esophageal Cancer, Canada, Market Size ($m), 2012-2019
Figure 42: Market for mAbs in Esophageal Cancer, Top Five European Markets, Treatment Usage Patterns, 2012-2019
Figure 43: Market for mAbs in Esophageal Cancer, Top Five European Markets, Annual Cost of Therapy ($), 2012-2019
Figure 44: Market for mAbs in Esophageal Cancer, Top Five European Markets, Market Size ($m), 2012-2019
Figure 45: Market for mAbs in Esophageal Cancer, Japan, Treatment Patterns, 2012-2019
Figure 46: Market for mAbs in Esophageal Cancer, Japan, Market Size ($m), 2012-2019
Figure 47: Market for mAbs in Gastric Cancer, Global, Licensing Deals (Countries), 2006-2013
Figure 48: Market for mAbs in Gastric Cancer, Global, Licensing Deals by Year and Value, 2006-2013
Figure 49: Market for mAbs in Gastrointestinal Tract Cancers, Global, Licensing Deals, 2006-2013
Figure 50: Market for mAbs in Gastric Cancer, Global, Co-Development Deals, 2006-2013
Figure 51: Research Market Forecasting Model

Ordering:


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Web Address: http://www.researchandmarkets.com/reports/2715077/
Office Code: SCH3Q6C8

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 7000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World